Table 2 Characteristics and dose volume data for patients with a locoregional failure
No. | Primary site | T stage | N stage | V95 of the PTV | Location of the Vf | Vf-V95* (site of failure) | Time to recurrence (months) |
|---|---|---|---|---|---|---|---|
1 | Oropharynx | T3 | N2b | 95% | In-field | 99% (N) | 8 |
2 | Larynx | T2 | N2c | 93% | In-field | 99% (N) | persistence |
3 | Oral cavity | T4 | N2c | 92% | In-field | 99% (T) | persistence |
4 | Larynx | T3 | N2c | 95% | Marginal | 50% (T) | 9 |
5 | Oropharynx | T4 | N3 | 97% | In-field | 100% (T + N) | 7 |
6 | Oral cavity | T4 | N0 | 98% | In-field | 99% (T) | 16 |
7 | Hypopharynx | T3 | N2c | 96% | In-field | 94% (N) | 15 |
8 | Oropharynx | T3 | N2b | 89% | In-field | 100% (N) | 15 |
9 | Oropharynx | T3 | N1 | 96% | In-field | 100% (N) | persistence |
10 | Oral cavity | T3 | N2a | 96% | In-field | 95% (T + N) | 10 |
11 | Larynx | T2 | N2b | 95% | In-field | 100% (T) 100% (N) | persistence |
12 | Oropharynx | T3 | N2b | 97% | In-field | 99% (T) | 8 |
13 | Hypopharynx | T3 | N2b | 99% | In-field | 100% (T + N) | 9 |